menadione topical lotion

DRUG2 trials

Sponsors

Spectrum Pharmaceuticals, Inc, Mayo Clinic

Conditions

Dermatologic ComplicationsEGFR Inhibitor-associated RashMalignant NeoplasmPain

Phase 1

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

CompletedNCT00656786

Spectrum Pharmaceuticals, IncEGFR Inhibitor-associated Rash

Start: 2008-04-03End: 2009-12-30Updated: 2020-11-13

Unknown Phase

Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

CompletedNCT01393821

Mayo ClinicDermatologic Complications, Malignant Neoplasm, Pain

Start: 2012-01-23End: 2018-07-14Updated: 2025-05-16